| Literature DB >> 36076175 |
Kenichiro Hira1,2, Yuji Ueno3, Masao Watanabe1, Hideki Shimura1, Naohide Kurita1, Nobukazu Miyamoto2, Haruna Haginiwa2, Kazuo Yamashiro1, Nobutaka Hattori2, Takao Urabe1.
Abstract
BACKGROUND: Embolic stroke of undetermined source (ESUS) encompasses diverse embologenic mechanisms, which transesophageal echocardiography (TEE) is critical to detect. Specific markers related to each embolic source in ESUS is not fully studied. We focused on D-dimer levels, and explored the association of D-dimer with potential embolic sources (PES) identified on TEE in ESUS.Entities:
Keywords: D-dimer; Embolic stroke of undetermined source; Patent foramen ovale; Transesophageal echocardiography
Mesh:
Substances:
Year: 2022 PMID: 36076175 PMCID: PMC9454212 DOI: 10.1186/s12883-022-02867-z
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.903
Fig. 1Flow diagram of the current study. TOAST, Trial of Org 10,172 in Acute Stroke Treatment; ESUS, embolic stroke of undetermined source; TEE, transesophageal echocardiography
Baseline characteristics and Laboratory and MRI findings according to the performance of TEE in ESUS
| Total | TEE examination | |||
|---|---|---|---|---|
| Variables | With | Without | ||
| Age, mean ± SD | 69.3 ± 13.2 | 66.6 ± 12.0 | 72.5 ± 13.9 | < 0.001 |
| Male gender, n (%) | 149 (71) | 89 (77) | 60 (63) | 0.018 |
| Hypertension, n (%) | 150 (71) | 83 (72) | 67 (70) | 0.704 |
| Diabetes mellitus, n (%) | 86 (41) | 52 (45) | 34 (35) | 0.149 |
| Dyslipidemia, n (%) | 155 (74) | 89 (78) | 66 (69) | 0.157 |
| Smoking, n (%) | 54 (26) | 30 (26) | 24 (25) | 0.857 |
| Chronic kidney disease, n (%) | 66 (31) | 30 (26) | 36 (38) | 0.075 |
| Coronary artery disease, n (%) | 6 (3) | 4 (3) | 2 (2) | 0.539 |
| Malignant tumor, n (%) | 13 (6) | 6 (5) | 7 (7) | 0.533 |
| History of cerebral infarction, n (%) | 40 (19) | 20 (17) | 20 (21) | 0.525 |
| 5.5 ± 6.5 | 3.9 ± 5.2 | 7.4 ± 7.2 | < 0.001 | |
| LDL-C, mg/dl, a | 112.9 ± 40.6 | 114.5 ± 36.3 | 110.8 ± 45.5 | 0.256 |
| HDL-C, mg/dl, a | 52.8 ± 15.9 | 51.5 ± 14.9 | 54.5 ± 16.9 | 0.217 |
| eGFR, ml/min | 69.2 ± 24.9 | 72.0 ± 25.4 | 65.7 ± 24.0 | 0.127 |
| Hemoglobin A1c, %, b | 6.2 ± 1.1 | 6.3 ± 1.1 | 6.1 ± 1.0 | 0.099 |
| BNP, pg/ml, c | 100.9 ± 265.9 | 110.1 ± 341.1 | 93.0 ± 137.6 | 0.046 |
| D-dimer, μg/ml, d | 2.7 ± 11.4 | 1.2 ± 1.3 | 2.9 ± 5.0 | < 0.001 |
| Multiple lesions | 116 (55) | 66 (57) | 50 (52) | 0.44 |
| Lesion size > 30 mm in diameter | 69 (33) | 38 (33) | 31 (32) | 0.908 |
| Cortical infarction | 167 (79) | 93 (81) | 74 (77) | 0.501 |
| Cerebral microbleeds | 43 (20) | 18 (16) | 25 (26) | 0.062 |
| PVH, grade ≥ 2 | 75 (36) | 32 (28) | 43 (45) | 0.01 |
| DSWMH, grade ≥ 2 | 69 (33) | 27 (23) | 42 (44) | 0.002 |
Chi-square test and the Mann−Whitney U test were used for comparison
Chronic kidney disease was defined as eGFR < 60 ml/min/1.73 m2. Missing values: a, n = 5; b, n = 4, c = 12, d = 6
MRI magnetic resonance imaging, TEE transesophageal echocardiography, ESUS embolic stroke of undetermined source, NIHSS National Institute Health stroke scale, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, eGFR estimated Glomerular Filtration Rate, BNP brain natriuretic peptide, PVH Periventricular hyperintensity, DSWMH deep and subcortical white matter hyperintensity
Multiple logistic regression analysis predicting a performance of TEE in ESUS
| Variables | OR | 95% CI | |
|---|---|---|---|
| Age | 0.99 | 0.96–1.02 | 0.544 |
| Male gender | 1.98 | 0.98–4.01 | 0.057 |
| Chronic kidney disease | 0.72 | 0.36–1.45 | 0.358 |
| NIHSS on admission | 0.93 | 0.88–0.98 | 0.008 |
| Hemoglobin A1c | 1.09 | 0.80–1.49 | 0.579 |
| BNP | 1.00 | 0.999–1.00 | 0.215 |
| D-dimer | 0.84 | 0.70–1.00 | 0.048 |
| Cerebral microbleeds | 0.72 | 0.32–1.62 | 0.425 |
| PVH, grade ≥ 2 | 1.2 | 0.4–3.64 | 0.748 |
| DSWMH, grade ≥ 2 | 0.4 | 0.15–1.30 | 0.137 |
OR odds ratio, CI confidence interval, TEE transesophageal echocardiography, ESUS embolic stroke of undetermined source, NIHSS National Institute Health stroke scale, BNP brain natriuretic peptide, PVH Periventricular hyperintensity, DSWMH deep and subcortical white matter hyperintensity
Baseline characteristics and Laboratory and MRI findings according to the presence of potential embolic sources in ESUS patients undergoing TEE
| Potential embolic sources | ||||
|---|---|---|---|---|
| Variables | None | One | ≥two | |
| Age, mean ± SD | 62.6 ± 8.7 | 66.2 ± 13.2 | 69.6 ± 10.8 | 0.024 |
| Male gender, n (%) | 19 (95) | 45 (74) | 25 (74) | 0.064 |
| Hypertension, n (%) | 17 (85) | 40 (66) | 26 (76) | 0.195 |
| Diabetes mellitus, n (%) | 12 (60) | 21 (34) | 19 (56) | 0.045 |
| Dyslipidemia, n (%) | 18 (90) | 44 (72) | 27 (79) | 0.239 |
| Smoking, n (%) | 7 (35) | 14 (23) | 9 (26) | 0.566 |
| Chronic kidney disease, n (%) | 4 (20) | 16 (26) | 10 (29) | 0.748 |
| Coronary artery disease, n (%) | 1 (5) | 2 (3) | 1 (3) | 0.923 |
| Malignant tumor, n (%) | 0 (0) | 5 (8) | 1 (3) | 0.173 |
| History of cerebral infarction, n (%) | 4 (20) | 7 (11) | 9 (26) | 0.171 |
| 2.7 ± 3.2 | 4.4 ± 6.3 | 3.6 ± 3.9 | 0.53 | |
| LDL-C, mg/dl, a | 128.6 ± 38.9 | 106.8 ± 35.2 | 119.6 ± 34.2 | 0.039 |
| HDL-C, mg/dl, a | 49.9 ± 17.1 | 52.3 ± 14.3 | 51.3 ± 15.1 | 0.798 |
| eGFR, ml/min | 71.9 ± 28.2 | 71.9 ± 25.1 | 72.5 ± 24.9 | 0.962 |
| Hemoglobin A1c, % | 6.4 ± 1.2 | 6.0 ± 0.7 | 6.7 ± 1.4 | 0.022 |
| BNP, pg/ml, b | 59.3 ± 77.0 | 86.4 ± 139.3 | 181.7 ± 593.4 | 0.739 |
| D-dimer, μg/ml, a | 0.6 ± 0.3 | 1.3 ± 1.5 | 1.3 ± 1.3 | 0.002 |
| Multiple lesions | 10 (50) | 38 (62) | 18 (53) | 0.516 |
| Lesion size > 30 mm in diameter | 5 (25) | 20 (33) | 13 (38) | 0.606 |
| Cortical infarction | 14 (70) | 50 (82) | 29 (85) | 0.367 |
| Cerebral microbleeds | 3 (15) | 8 (13) | 7 (21) | 0.628 |
| PVH, grade ≥ 2 | 5 (25) | 17 (28) | 10 (29) | 0.941 |
| DSWMH, grade ≥ 2 | 6 (18) | 12 (20) | 9 (26) | 0.567 |
Chi-square test and the Mann−Whitney U test were used for comparison
Chronic kidney disease was defined as eGFR < 60 ml/min/1.73 m2. Missing values: a, n = 2; b, n = 8
MRI magnetic resonance imaging, ESUS embolic stroke of undetermined source, TEE transesophageal echocardiography, NIHSS National Institute Health stroke scale, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, eGFR estimated Glomerular Filtration Rate, BNP brain natriuretic peptide, PVH Periventricular hyperintensity, DSWMH deep and subcortical white matter hyperintensity
Multinomial logistic regression analysis predicting factors associated with one and more than two potential embolic sources
| Potential embolic sources | ||||||
|---|---|---|---|---|---|---|
| One vs. None | ≥two vs. None | |||||
| Variables | OR | 95% CI | OR | 95% CI | ||
| Age | 1.01 | 0.96–1.07 | 0.689 | 1.06 | 0.99–1.13 | 0.122 |
| Male gender | 0.16 | 0.02–1.54 | 0.112 | 0.17 | 0.02–1.71 | 0.132 |
| Diabetes mellitus | 0.26 | 0.05–1.24 | 0.091 | 0.24 | 0.04–1.31 | 0.099 |
| LDL-C | 0.98 | 0.96–1.00 | 0.012 | 0.99 | 0.97–1.01 | 0.257 |
| Hemoglobin A1c | 1.00 | 0.45–2.22 | 0.999 | 2.05 | 0.98–4.31 | 0.058 |
| D-dimer | 9.01 | 1.00–81.51 | 0.05 | 9.76 | 1.07–88.97 | 0.043 |
OR odds ratio, CI confidence interval, LDL-C low-density lipoprotein cholesterol
Fig. 2Comparison in D-dimer levels between patients with and without RLS. Distributions of D-dimer levels in patients without RLS (0.94 ± 0.74 μg/ml), and with RLS (1.37 ± 1.64 μg/ml, A), and RLS with < 20 MBs (1.33 ± 1.66 μg/ml) and with ≥20 MBs (1.61 ± 1.58 μg/ml, B), and RLS without DVT (1.20 ± 1.55 μg/ml) and with DVT (2.99 ± 1.92 μg/ml, C). RLS = right-to-left shunt; MBs = microbubbles; DVT = deep venous thrombosis
Baseline characteristics and Laboratory and MRI findings according to the plasma D-dimer levels in ESUS patients undergoing TEE
| Total | D-dimer levels | |||
|---|---|---|---|---|
| Variables | ≤ 1.0 μg/ml | > 1.0 μg/ml | ||
| Age, y | 66.9 ± 11.8 | 66.3 ± 10.5 | 68.0 ± 14.3 | 0.153 |
| Male gender, n (%) | 87 (77) | 63 (84) | 24 (63) | 0.013 |
| Hypertension, n (%) | 82 (73) | 57 (76) | 25 (66) | 0.25 |
| Diabetes mellitus, n (%) | 52 (46) | 35 (47) | 17 (45) | 0.846 |
| Dyslipidemia, n (%) | 88 (78) | 58 (77) | 30 (79) | 0.846 |
| Smoking, n (%) | 29 (26) | 21 (28) | 8 (21) | 0.424 |
| Chronic kidney disease, n (%) | 29 (26) | 14 (19) | 15 (39) | 0.017 |
| Coronary artery disease, n (%) | 4 (4) | 2 (3) | 2 (5) | 0.492 |
| Malignant tumor, n (%) | 6 (5) | 1 (1) | 5 (13) | 0.01 |
| History of cerebral infarction, n (%) | 20 (18) | 9 (12) | 11 (29) | 0.026 |
| 3.9 ± 5.3 | 3.2 ± 4.2 | 5.1 ± 6.8 | 0.084 | |
| LDL-C, mg/dl, a | 114.7 ± 36.6 | 114.7 ± 36.6 | 114.8 ± 37.2 | 0.997 |
| HDL-C, mg/dl, a | 51.6 ± 14.9 | 53.2 ± 15.9 | 48.5 ± 12.2 | 0.123 |
| eGFR, ml/min | 72.1 ± 25.3 | 75.8 ± 21.9 | 64.7 ± 29.8 | 0.052 |
| Hemoglobin A1c, % | 6.3 ± 1.1 | 6.4 ± 1.2 | 6.1 ± 0.8 | 0.353 |
| BNP, pg/ml, b | 110.9 ± 342.7 | 68.8 ± 118.9 | 196.1 ± 567.7 | 0.058 |
| Multiple lesions | 66 (58) | 44 (59) | 22 (58) | 0.937 |
| Lesion size > 30 mm in diameter | 38 (34) | 21 (28) | 17 (45) | 0.075 |
| Cortical infarction | 92 (81) | 61 (81) | 31 (82) | 0.975 |
| Cerebral microbleeds | 18 (16) | 12 (16) | 6 (16) | 0.977 |
| PVH, grade ≥ 2 | 32 (28) | 20 (27) | 12 (32) | 0.584 |
| DSWMH, grade ≥ 2 | 27 (24) | 17 (23) | 10 (26) | 0.667 |
| RLS | 59 (52) | 34 (45) | 25 (66) | 0.04 |
| Degree of shunt | 0.116 | |||
| Small to Intermediate | 51 (45) | 30 (40) | 21 (55) | |
| Large | 8 (7) | 4 (5) | 4 (11) | |
| Comorbidity with DVT | 0.013 | |||
| RLS without DVT | 51 (45) | 32 (43) | 19 (50) | |
| Both RLS and DVT | 8 (7) | 2 (3) | 6 (16) | |
| Atrial septal aneurysm | 8 (7) | 4 (5) | 4 (11) | 0.322 |
| Aortic arch plaques | 53 (47) | 35 (47) | 18 (47) | 0.944 |
| LAA dysfunction or SEC | 9 (8) | 6 (8) | 3 (8) | 0.984 |
Chi-square test and the Mann−Whitney U test were used for comparison
Chronic kidney disease was defined as eGFR < 60 ml/min/1.73 m2. Missing values: a, n = 2; b, n = 7
MRI magnetic resonance imaging, ESUS embolic stroke of undetermined source, TEE transesophageal echocardiography, NIHSS National Institute Health stroke scale, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, eGFR estimated Glomerular Filtration Rate, BNP brain natriuretic peptide, PVH Periventricular hyperintensity, DSWMH deep and subcortical white matter hyperintensity, RLS right-to-left shunt, DVT deep venous thrombosis, LAA left atrial appendage, SEC spontaneous echo contrast
Multiple logistic regression analysis predicting an elevation of plasma D-dimer levels
| Variables | OR | 95% CI | |
|---|---|---|---|
| Male gender | 0.48 | 0.15–1.52 | 0.21 |
| Chronic kidney disease | 1.63 | 0.34–7.91 | 0.541 |
| Malignant tumor | 6.25 | 0.59–66.76 | 0.129 |
| History of cerebral infarction | 3.63 | 1.03–12.84 | 0.046 |
| NIHSS on admission | 1.08 | 0.98–1.18 | 0.111 |
| eGFR | 0.97 | 0.94–1.00 | 0.087 |
| BNP | 1 | 1.00–1.01 | 0.403 |
| Lesion size > 30 mm in diameter | 2.13 | 0.75–6.05 | 0.155 |
| RLS | 4.62 | 1.46–14.61 | 0.009 |
| Male gender | 0.49 | 0.15–1.61 | 0.242 |
| Chronic kidney disease | 1.66 | 0.34–8.19 | 0.536 |
| Malignant tumor | 6.21 | 0.56–69.27 | 0.138 |
| History of cerebral infarction | 3.55 | 1–12.57 | 0.05 |
| NIHSS on admission | 1.07 | 0.98–1.18 | 0.153 |
| eGFR | 0.97 | 0.94–1.01 | 0.093 |
| BNP | 1.00 | 1.00–1.01 | 0.348 |
| Lesion size > 30 mm in diameter | 2.04 | 0.71–5.91 | 0.188 |
| RLS | |||
| Without DVT | 3.9 | 1.20–12.70 | 0.024 |
| With DVT | 13.94 | 1.77–109.99 | 0.012 |
OR odds ratio, CI confidence interval, eGFR estimated Glomerular Filtration Rate, BNP brain natriuretic peptide, RLS Right-to-left shunt, DVT deep venous thrombosis